

Baxter International Inc.
Key Product Line Sales
Period Ending June 30, 2005
(unaudited)

(\$ in millions)	Q2 2005	Q2 2004	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2005	YTD 2004	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$397	\$320	24%	20%	\$741	\$612	21%	17%
Plasma Proteins ¹	266	267	-%	(3%)	525	505	4%	1%
Antibody Therapy	93	90	3%	1%	182	170	7%	4%
Transfusion Therapies	140	136	3%	1%	273	276	(1%)	(4%)
Other ²	94	80	18%	10%	171	140	22%	17%
Total BioScience	\$990	\$893	11%	7%	\$1,892	\$1,703	11%	8%
Medication Delivery								
IV Therapies ³	\$312	\$288	8%	4%	\$608	\$570	7%	3%
Drug Delivery	226	202	12%	11%	430	390	10%	9%
Infusion Systems	245	233	5%	3%	475	421	13%	11%
Anesthesia	282	259	9%	7%	513	501	2%	1%
Other ⁴	18	24	(25%)	(33%)	35	50	(30%)	(32%)
Total Medication Delivery ⁵	\$1,083	\$1,006	8%	5%	\$2,061	\$1,932	7%	4%
Renal								
PD Therapy	\$385	\$357	8%	3%	\$759	\$702	8%	4%
HD Therapy	114	118	(3%)	(8%)	240	242	(1%)	(6%)
Other	5	5	-%	-%	8	9	(11%)	(11%)
Total Renal	\$504	\$480	5%	-%	\$1,007	\$953	6%	1%
TOTAL BAXTER	\$2,577	\$2,379	8%	5%	\$4,960	\$4,588	8%	5%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes other hospital-distributed products.

⁵ Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.